Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/133589
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Identification of a novel GOLGA4–JAK2 fusion gene in B-cell acute lymphoblastic leukaemia |
Author: | Downes, C.E.J. Rehn, J. Heatley, S.L. Yeung, D. McClure, B.J. White, D.L. |
Citation: | British Journal of Haematology, 2022; 196(3):700-705 |
Publisher: | Wiley |
Issue Date: | 2022 |
ISSN: | 0007-1048 1365-2141 |
Statement of Responsibility: | Charlotte E.J. Downes, Jacqueline Rehn, Susan L. Heatley, David Yeung, Barbara J. McClure, Deborah L. White |
Abstract: | Rearrangements of Janus kinase 2 (JAK2r) form a subtype of acute lymphoblastic leukaemia (ALL) associated with poor patient outcomes. We present a high-risk case of B-cell ALL (B-ALL) where retrospective mRNA sequencing identified a novel GOLGA4–JAK2 fusion gene. Expression of GOLGA4–JAK2 in murine pro-B cells promoted factor-independent growth, implicating GOLGA4–JAK2 as an oncogenic driver. Cells expressing GOLGA4–JAK2 demonstrated constitutive activation of JAK/STAT signalling and were sensitive to JAK inhibitors. This study contributes to the diverse collection of JAK2 fusion genes identified in B-ALL and supports the incorporation of JAK inhibitors into treatment strategies to improve outcomes for this subtype. |
Keywords: | Acute leukaemia; tyrosine kinases; chromosomal; rearrangements; gene fusion; JAK2; targeted therapy |
Description: | First published: 25 October 2021 |
Rights: | © 2021 British Society for Haematology and John Wiley & Sons Ltd |
DOI: | 10.1111/bjh.17910 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/1057746 |
Published version: | http://dx.doi.org/10.1111/bjh.17910 |
Appears in Collections: | Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.